ACTRN12623001110673招募中2 期
A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1)Diagnosis of AIS deemed suitable for endovascular revascularization (mechanical thrombectomy with or without a thrombolytic agent).
- •2)Aged >/= 18 years.
- •3)Stroke onset (last known well) time < /= 24 hours before randomization.
- •4)The National Institutes of Health Stroke Scale (NIHSS) >/= 5 points at time of randomization.
- •5)Pre-stroke modified Rankin Score (mRS) < /= 3. Participant must have been living in their own home, apartment, or a senior’s lodge where no nursing care is required.
- •6)Confirmed symptomatic intracranial occlusion, based on computed tomographic angiography (CTA), at one or more of the following locations: intracranial internal carotid artery (T/L morphology) or M1 middle cerebral artery.
- •7)For participants transferring to stroke center from another hospital, CTA for study eligibility is to be performed or repeated at stroke center with endovascular suite onsite if there is a long delay (> 6 hours) from time of first CTA to time of repeat CTA.
- •8)Signed informed consent from participant or their legally authorized representative, or if required to enable inclusion by applicable national laws and regulations and the applicable Institutional Review Board/Ethics Committee requirements for obtaining consent from the investigator after consultation with an independent physician who is not otherwise participating in the study.
- •9)Willing (participant and/or caretaker) to commit to follow up assessments.
排除标准
- •1)Evidence of a large core of established infarction defined as ASPECTS of 0 to 5.
- •2)Evidence of intracranial hemorrhage or mass lesion on the qualifying imaging.
- •3)Endovascular revascularization procedure has already been completed at the time of Screening/randomization or has been completed before administration of study drug.
- •4)Planned use of an endovascular device that is not approved or does not have clearance by the relevant regulatory authority.
- •5)Rapid spontaneous improvement of neurological signs during Screening, as defined by a reduction of >/= 8 on the NIHSS between onset of symptoms and randomization.
- •6)History of stroke (ischemic or hemorrhagic) or penetrating head injury within 90 days before enrollment.
- •7)Uncontrolled blood pressure (BP) >/= 180/110 mmHg before endovascular revascularization procedure is initiated.
- •8)No femoral pulses, very difficult endovascular access, or extreme tortuosity of the great vessels that is predicted to result in an inability to timely deliver endovascular therapy. Direct common carotid or radial/brachial/axillary access is permissible.
- •9)Estimated or known body weight < 45 kg or > 130 kg.
- •10)Pregnancy: If a woman is of childbearing potential and has a positive point-of-care urine beta-human chorionic gonadotropin (ß-HCG) test or is breastfeeding.
- •11)Severe known renal impairment defined as requiring dialysis (hemo- or peritoneal) or a creatinine clearance < 29 mL/min.
- •12)Severe or fatal comorbid illness that will prevent improvement or follow-up.
- •13)Cannot complete follow-up visits because participant is a visitor to the area, or any other known reason that would prevent attendance at follow-up visits.
- •14)Received treatment with an investigational drug or device within 30 days before enrollment.
- •15)Any other condition that, in the opinion of the investigator, may adversely affect the safety of the participant, the participant’s ability to complete the study, or the outcome of the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary InterventioEUCTR2007-002208-17-NLDanube Pharmaceuticals60
招募中
1 期
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara)Delayed graft functionMedDRA version: 21.0Level: PTClassification code: 10076664Term: Delayed graft function Class: 100000004863MedDRA version: 21.1Level: LLTClassification code: 10048747Term: Renal graft function delayed Class: 10022117CTIS2022-503091-89-00Argenx108
进行中（未招募）
1 期
A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - N/APatients with Coronary Heart Disease (CHD) or CHD Risk EquivalentsMedDRA version: 9.1Level: HLGTClassification code 10013317Term: Lipid metabolism disordersEUCTR2007-003406-10-FRF.Hoffmann-La Roche Ltd.450
进行中（未招募）
不适用
A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - N/AEUCTR2007-003406-10-ATF.Hoffmann-La Roche Ltd.450
进行中（未招募）
1 期
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyMedDRA version: 12.1Level: LLTClassification code 10064060Term: Multiple system atrophyMultiple system atrophyEUCTR2009-018157-23-ATAstraZeneca AB120